Denali therapeutics appoints alexander schuth as chief operating and financial officer as steve krognes transitions to denali board of directors

South san francisco, calif., march 15, 2022 (globe newswire) -- denali therapeutics inc. (nasdaq: dnli), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (bbb) for neurodegenerative diseases, today announced that steve krognes will transition from his role as chief financial officer (cfo) and join the company's board of directors on may 1, 2022. denali's chief operating officer alexander schuth, m.d., will add the chief financial officer role to his current responsibilities, becoming denali's chief operating and financial officer.
DNLI Ratings Summary
DNLI Quant Ranking